Fig. 2From: Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosisPatient screening process, * Methods to exclude secondary PAP: Medical history was inquired to exclude genetic factors; to inquire whether there is a history of industrial dust exposure and ask pneumonologists to help exclude occupational pneumoconiosis; Microbial examination was performed to exclude secondary PAP changes caused by viruses, bacteria, fungi, tuberculosis and other infections through sputum, bronchoalveolar lavage fluid, blood and other samplesBack to article page